Podium to Practice: ESMO® 2025 – GU: RAMPART
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Speakers
Studies / Trials Discussed
LBA93 – First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
Studies/trials discussed:
LBA93 – First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.